1 / 1

4,155

Brand Name (Generic name). 분야. 개발사. Sales($million). 2003. 2004. 2007. 2010. Rituxan (Rituximab). Oncology. Biogen-IDEC. 2,122. 2,794. 2,315. 4,079. Remicade (infliximab). AIID. Centocor/ Schering Plough. 2,048. 2,613. -. 4,180. Herceptin (trastuzumab). oncology.

yelena
Télécharger la présentation

4,155

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Brand Name(Generic name) 분야 개발사 Sales($million) 2003 2004 2007 2010 Rituxan (Rituximab) Oncology Biogen-IDEC 2,122 2,794 2,315 4,079 Remicade (infliximab) AIID Centocor/ Schering Plough 2,048 2,613 - 4,180 Herceptin (trastuzumab) oncology Genentech 978 1,234 1,767 1,716 Synagis (palivizumab) Infectious disease Medimmune 849 1,015 - 1,413 Humira (adalimumab) AIID Abbot 280 852 2,392 4,155 Avastin (bevacizumab) Oncology Genentech n/l 545 2,674 3,911 치료용 항체의 매출현황 Source : Datamonitor, 2005

More Related